NeoGenomics, Inc. (NEO)
$16.66+2.84%Close
SELLRECOVERY · day 1
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $434M
- Beta
- 1.78
- P/E (TTM)
- -8.40
- Short % float
- 59.82%
- Days to cover
- 5.7
- SI change
- -15.3%
- 1W
- +0.91%
- 1M
- -9.51%
- vs SPY 1W
- +1.05%
- vs SPY 1M
- -12.01%
Industry peers
FMP comparable companies · ranked by market cap
- GHSELLGuardant Health, Inc.$21.8BBEARQ 23$162.09-0.43%
- GRALBUYGRAIL Inc.$6.0BRECOVERYQ 68$140.35+2.17%
- VCYTBUYVeracyte, Inc.$3.4BBEARQ 14$43.11-2.07%
- WGSSELLGeneDx Holdings Corp.$1.9BCRISISQ -3$64.96+1.79%
- PSNLSELLPersonalis, Inc.$1.7BBEARQ 6$15.85+0.32%
- CSTLSELLCastle Biosciences, Inc.$1.0BRECOVERYQ 11$32.88+0.37%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
FAQ
- What is LOPJLB’s current signal on NEO?
- LOPJLB’s latest quantitative signal on NeoGenomics, Inc. (NEO) is SELL in a RECOVERY regime. Signals are updated daily.
- What market regime is NEO in?
- NeoGenomics, Inc. (NEO) is currently classified in the RECOVERY HMM market regime on LOPJLB.
- What does NeoGenomics, Inc. (NEO) do?
- NeoGenomics, Inc. specializes in providing cancer-focused diagnostic and testing services through an extensive network of laboratories located across the United States, Europe, and Asia. The company operates through two distinct divisions: Clinical Services and Pharma Services. Its comprehensive offerings cater to a diverse clientele, including hospitals, reference laboratories, pathologists, o…